Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Double trial disappointment for Roche

Double trial disappointment for Roche The regimens were Kadcyla plus Roche's Perjeta (pertuzumab), Kadcyla alone and Herceptin plus taxane chemotherapy.

Novartis' Afinitor fails frontline breast cancer trial

Novartis' Afinitor fails frontline breast cancer trial Afinitor conferred a seven-month improvement in PFS, and while this may warrant further study emerging data for other treatment regimens - such as the combination of Herceptin with Roche's Perjeta

NHS names drugs to be re-evaluated for Cancer Drugs Fund

NHS names drugs to be re-evaluated for Cancer Drugs Fund Kadcyla (trastuzumab emtansine). Breast cancer. Perjeta (pertuzumab). Breast cancer. Sanofi. Jevtana (cabazitaxel).

SMC fails to recommend Roche’s Perjeta

SMC fails to recommend Roche’s Perjeta Says drug is not a cost-effective option in breast cancer. The Scottish Medicines Consortium (SMC) has not recommended Roche's Perjeta for use in the treatment of unresectable breast cancer. ... Perjeta demonstrated "phenomenal" results at the European

BMS taps F-star Alpha for immuno-oncology drug

BMS taps F-star Alpha for immuno-oncology drug FS102 works differently to current HER2-targeted therapies such as Roche's Herceptin (trastuzumab) and Perjeta (pertuzumab), and is being developed specifically to meet the problem of resistance to those drugs.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics